Aumolertinib is an irreversible inhibitor of EGFR tyrosine kinase.
The active ingredient is intended for the treatment of non-small cell lung cancer (NSCLC).
The active ingredient targets specific activating EGFR mutations, including exon 19 deletions (Ex19Del) and the L858R mutation, as well as the T790M resistance mutation.
Positive recommendation by the EMA in November 2026.